JP2022528030A5 - - Google Patents
Info
- Publication number
- JP2022528030A5 JP2022528030A5 JP2021539880A JP2021539880A JP2022528030A5 JP 2022528030 A5 JP2022528030 A5 JP 2022528030A5 JP 2021539880 A JP2021539880 A JP 2021539880A JP 2021539880 A JP2021539880 A JP 2021539880A JP 2022528030 A5 JP2022528030 A5 JP 2022528030A5
- Authority
- JP
- Japan
- Prior art keywords
- component
- fusion protein
- protein according
- seq
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962789212P | 2019-01-07 | 2019-01-07 | |
| US62/789,212 | 2019-01-07 | ||
| PCT/US2020/012624 WO2020146423A1 (en) | 2019-01-07 | 2020-01-07 | Multi-functional fusion proteins and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022528030A JP2022528030A (ja) | 2022-06-08 |
| JP2022528030A5 true JP2022528030A5 (enExample) | 2022-12-26 |
| JP7587505B2 JP7587505B2 (ja) | 2024-11-20 |
Family
ID=71521906
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021539880A Active JP7587505B2 (ja) | 2019-01-07 | 2020-01-07 | 多機能性融合タンパク質及びその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US12497439B2 (enExample) |
| EP (1) | EP3908664A4 (enExample) |
| JP (1) | JP7587505B2 (enExample) |
| KR (2) | KR20260116815A (enExample) |
| CN (1) | CN113518823B (enExample) |
| AU (2) | AU2020207265B2 (enExample) |
| BR (1) | BR112021013415A2 (enExample) |
| CA (1) | CA3125748A1 (enExample) |
| IL (1) | IL284679A (enExample) |
| MX (1) | MX2021008207A (enExample) |
| SG (1) | SG11202107454UA (enExample) |
| WO (1) | WO2020146423A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2916217T3 (es) | 2017-01-05 | 2022-06-29 | Kahr Medical Ltd | Una proteína de fusión SIRP1 ALPHA-41BBL y métodos de uso de la misma |
| DK3565579T3 (da) | 2017-01-05 | 2023-09-04 | Kahr Medical Ltd | Pd1-41bbl-fusionsprotein og fremgangsmåder til anvendelse deraf |
| US11299530B2 (en) | 2017-01-05 | 2022-04-12 | Kahr Medical Ltd. | SIRP alpha-CD70 fusion protein and methods of use thereof |
| US11566060B2 (en) | 2017-01-05 | 2023-01-31 | Kahr Medical Ltd. | PD1-CD70 fusion protein and methods of use thereof |
| IL280102B1 (en) | 2018-07-11 | 2026-07-01 | Kahr Medical Ltd | Fusion protein containing PD1-4-1BBL and methods of using the same |
| CA3104780A1 (en) | 2018-07-11 | 2020-01-16 | Kahr Medical Ltd. | Sirpalpha-4-1bbl variant fusion protein and methods of use thereof |
| CN113518823B (zh) | 2019-01-07 | 2025-05-02 | 托马斯杰斐逊大学 | 多功能的融合蛋白及其用途 |
| EP4175656A4 (en) * | 2020-07-03 | 2024-10-16 | The Trustees of Columbia University in the City of New York | POLYFUNCTIONAL ORTHOGONAL PROTEIN CHIMERA |
| US20240076346A1 (en) * | 2021-01-13 | 2024-03-07 | Kahr Medical Ltd. | Type i membrane proteins heterodimers and methods of use thereof |
| WO2022188129A1 (zh) * | 2021-03-12 | 2022-09-15 | 利时雨 | 广谱趋化因子受体抑制剂增强新冠肺炎病毒感染的细胞免疫的分子机制及在其药物防治中的应用 |
| CN118369336A (zh) * | 2022-04-15 | 2024-07-19 | Im生技股份有限公司 | 具有改进半衰期的融合蛋白平台 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001056591A1 (en) | 2000-02-03 | 2001-08-09 | Thomas Jefferson University | vMIP-II PEPTIDE ANTAGONISTS OF CXCR4 |
| US7897152B2 (en) * | 2000-09-18 | 2011-03-01 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Viral chemokine-antigen fusion proteins |
| US8021658B2 (en) * | 2001-05-25 | 2011-09-20 | Thomas Jefferson University | Alternative splice forms of proteins as basis for multiple therapeutic modalities |
| CN105837690A (zh) | 2006-06-12 | 2016-08-10 | 新兴产品开发西雅图有限公司 | 具有效应功能的单链多价结合蛋白 |
| DE102009047243A1 (de) | 2009-11-27 | 2011-06-01 | Orgentec Diagnostika Gmbh | Monospezifische Polypeptidreagenzien |
| EP2950814A4 (en) | 2013-01-31 | 2016-06-08 | Univ Jefferson | FUSION PROTEINS BASED ON PD-L1 AND PD-L2 AND USES THEREOF |
| EP3030322A2 (en) | 2013-08-05 | 2016-06-15 | Cambridge Enterprise Limited | Inhibition of cxcr4 signaling in cancer immunotherapy |
| US20180179282A1 (en) | 2015-06-12 | 2018-06-28 | Bristol-Myers Squibb Company | Treatment of cancer by combined blockade of the pd-1 and cxcr4 signaling pathways |
| CN109608544B (zh) * | 2015-11-17 | 2022-09-16 | 苏州盛迪亚生物医药有限公司 | Pd-l1抗体、其抗原结合片段及其医药用途 |
| GB201521383D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl And Ucb Celltech | Method |
| JP6732915B2 (ja) * | 2015-12-15 | 2020-07-29 | ギリアード サイエンシーズ， インコーポレイテッド | ヒト免疫不全ウイルス中和抗体 |
| US11365237B2 (en) * | 2016-03-23 | 2022-06-21 | Helmholtz Zentrum Muenchen—Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt (Gmbh) | Fusion proteins of PD-1 and 4-1BB |
| US11124577B2 (en) * | 2016-11-02 | 2021-09-21 | Engmab Sàrl | Bispecific antibody against BCMA and CD3 and an immunological drug for combined use in treating multiple myeloma |
| RU2665790C1 (ru) | 2017-04-17 | 2018-09-04 | Закрытое Акционерное Общество "Биокад" | Моноклональное антитело к pd-l1 |
| WO2018209017A1 (en) * | 2017-05-10 | 2018-11-15 | The General Hospital Corporation | Cancer treatment with a cxcl12 signaling inhibitor and an immune checkpoint inhibitor |
| RU2766590C2 (ru) * | 2017-05-16 | 2022-03-15 | Цзянсу Хэнжуй Медисин Ко., Лтд. | Фармацевтическая композиция на основе антитела к pd-l1 и ее применение |
| US20200140547A1 (en) * | 2017-05-26 | 2020-05-07 | The Johns Hopkins University | Multifunctional antibody-ligand traps to modulate immune tolerance |
| GB201709808D0 (en) * | 2017-06-20 | 2017-08-02 | Kymab Ltd | Antibodies |
| JP7009517B2 (ja) | 2017-06-21 | 2022-01-25 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｉｖ ｇｐ１２０およびｃｄ３を標的とする多重特異性抗体 |
| CN113518823B (zh) | 2019-01-07 | 2025-05-02 | 托马斯杰斐逊大学 | 多功能的融合蛋白及其用途 |
-
2020
- 2020-01-07 CN CN202080016520.5A patent/CN113518823B/zh active Active
- 2020-01-07 AU AU2020207265A patent/AU2020207265B2/en active Active
- 2020-01-07 BR BR112021013415A patent/BR112021013415A2/pt unknown
- 2020-01-07 WO PCT/US2020/012624 patent/WO2020146423A1/en not_active Ceased
- 2020-01-07 JP JP2021539880A patent/JP7587505B2/ja active Active
- 2020-01-07 MX MX2021008207A patent/MX2021008207A/es unknown
- 2020-01-07 KR KR1020267024064A patent/KR20260116815A/ko active Pending
- 2020-01-07 US US17/421,053 patent/US12497439B2/en active Active
- 2020-01-07 EP EP20738361.3A patent/EP3908664A4/en active Pending
- 2020-01-07 SG SG11202107454UA patent/SG11202107454UA/en unknown
- 2020-01-07 KR KR1020217024898A patent/KR102996287B1/ko active Active
- 2020-01-07 CA CA3125748A patent/CA3125748A1/en active Pending
-
2021
- 2021-07-07 IL IL284679A patent/IL284679A/en unknown
-
2025
- 2025-11-04 US US19/378,976 patent/US20260193312A1/en active Pending
-
2026
- 2026-06-23 AU AU2026204884A patent/AU2026204884A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wei et al. | Current landscape and future directions of bispecific antibodies in cancer immunotherapy | |
| JP7781243B2 (ja) | ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法 | |
| JP7356970B2 (ja) | 多重特異性抗体とその作製及び使用方法 | |
| JP7685095B2 (ja) | 多重特異性抗体とその作製及び使用方法 | |
| JP7757247B2 (ja) | ヒト化またはキメラｃｄ３抗体 | |
| JP7399852B2 (ja) | 多重特異性抗体とその作製及び使用方法 | |
| JP2024023317A (ja) | 二重特異性抗体の組成物及びその使用方法 | |
| JP2023523628A5 (enExample) | ||
| JP2019514846A (ja) | 免疫チェックポイントモジュレーターとのｔ細胞リダイレクティング多機能抗体の組み合わせとその使用 | |
| JP2022527081A5 (enExample) | ||
| US20240156863A1 (en) | Sequential anti-cd19 therapy | |
| WO2020263879A1 (en) | Antibodies for t-cell activation | |
| JP2023547506A5 (enExample) | ||
| US20240101701A1 (en) | Antibody-derived t cell activating technologies | |
| JP2024535740A5 (enExample) | ||
| RU2021121848A (ru) | Многофункциональные слитые белки и их применения | |
| CA3250429A1 (en) | MODIFIED CYTOXIC T LYMPHOCYTES AND ASSOCIATED METHODS OF USE | |
| RU2024106039A (ru) | Многофункциональные слитые белки и их применения | |
| Shuptrine et al. | Bifunctional antibodies: preclinical and clinical applications | |
| HK40018991A (en) | Multi-specific antibodies and methods of making and using thereof |